Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




New Technique Predicts Aggressive Tumors Before They Metastasize

By LabMedica International staff writers
Posted on 25 Feb 2025

Tumors are held together by a structure known as the extracellular matrix (ECM), which serves as a supportive framework, similar to scaffolding around a building under construction. More...

New research has uncovered how the tumor environment alters cancer cells, allowing them to change shape and escape the tumor. This discovery opens the door for developing treatments that can target cancer before it has a chance to spread.

A team of researchers from The Institute of Cancer Research London (London, UK) and Barts Cancer Institute at Queen Mary University of London (BCI-QMUL, London, UK) explored how cancer cells use the arrangement of the ECM as a guide to leave the tumor. They found that the ECM triggers changes inside the cancer cells, altering their shape and enhancing their ability to move to other parts of the body. This breakthrough means that tumors likely to metastasize can now be identified earlier, enabling doctors to tailor treatments sooner. Drugs targeting the ECM’s structure, as well as the genes responsible for these shape changes, are currently in development, offering the potential to stop cancer before it can spread.

For their study, the research team examined tumor tissue from 99 patients with melanoma and breast cancer. They observed that the ECM was arranged differently in three distinct regions of the tumor. Like scaffolding, the ECM contains various components, including pole-like fibers. In the tumor’s core, the fibers were spread out and disorganized, while at the edges, they were tightly packed and thicker. At the outermost edge of the tumor, the fibers were oriented outward, providing a ‘pathway’ for cancer cells to escape. In this outer region, the cancer cells were rounded, a shape associated with increased invasiveness.

The team tested whether the conditions at the tumor’s border contributed to the aggressiveness of the cancer cells. They grew melanoma cells in a model that mimicked these conditions and injected them into mice. Cells grown under these conditions were more likely to spread to the lungs and metastasize compared to cells grown in control conditions with disorganized ECM fibers. The researchers also found that cells from the tumor’s outer edge had distinct gene profiles. These cells expressed more genes related to cell migration, cell rounding, and inflammation—traits that make the cells more aggressive and better equipped to survive. Furthermore, the team observed an increase in genes for enzymes that affect the organization of the ECM, highlighting how cancer cells manipulate their environment to facilitate tumor escape.

When the researchers compared their findings to cancers from patients with 14 different tumor types, including melanoma, breast, pancreatic, lung cancer, and glioblastoma—a highly aggressive brain cancer—they discovered that a higher presence of these genes was linked to a shorter survival time. Published in Nature Communications, these results suggest new treatment possibilities to address cancer before it spreads. One promising avenue is targeting lysyl oxidase (LOX) enzymes, which stabilize the ECM and are more prevalent at the tumor’s border. Drugs targeting LOX are already undergoing clinical trials for other medical conditions, offering hope for potential use in cancer treatment.

“Our research has uncovered the roadmap that cancer cells follow to break out of a tumor, enabling it to cause a secondary tumor elsewhere in the body," said Professor Victoria Sanz Moreno, Professor of Cancer Cell and Metastasis Biology at The Institute of Cancer Research. “Now that we understand this roadmap, we can look to target different aspects of it, to stop aggressive cancers from spreading.”


New
Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Rapid Molecular Testing Device
FlashDetect Flash10
New
Anterior Nasal Specimen Collection Swabs
53-1195-TFS, 53-0100-TFS, 53-0101-TFS, 53-4582-TFS
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The ONC IN-CYT platform leverages cross indication biomarker cyto-signatures (Photo courtesy of OraLiva)

AI-Powered Cytology Tool Detects Early Signs of Oral Cancer

Each year, 54,000 Americans are diagnosed with oral cancer, yet only 28% of cases are identified at an early stage, when the five-year survival rate exceeds 85%. Most diagnoses occur in later stages, when... Read more

Hematology

view channel
Image: The microfluidic device for passive separation of platelet-rich plasma from whole blood (Photo courtesy of University of the Basque Country)

Portable and Disposable Device Obtains Platelet-Rich Plasma Without Complex Equipment

Platelet-rich plasma (PRP) plays a crucial role in regenerative medicine due to its ability to accelerate healing and repair tissue. However, obtaining PRP traditionally requires expensive centrifugation... Read more

Immunology

view channel
Image: PD-1 protein blockade is the standard treatment for advanced melanoma among the different types of immunotherapy (Photo courtesy of 123RF)

Precision Tool Predicts Immunotherapy Treatment Failure in Melanoma Patients

Melanoma, though accounting for only about 4% of skin tumors, is the deadliest form of skin cancer due to its high potential to metastasize. While immunotherapy, especially PD-1 protein blockade, has revolutionized... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.